StemCells Inc. (NASDAQ:STEM) had its price objective lifted by S&P Equity Research from $1.07 to $1.20 in a research note issued to investors on Thursday morning.

Shares of StemCells (NASDAQ:STEM) opened at 1.02 on Thursday. The stock’s market capitalization is $12.25 million. The stock’s 50 day moving average price is $1.39 and its 200-day moving average price is $1.58. StemCells has a 12 month low of $0.33 and a 12 month high of $7.56.

StemCells Company Profile

StemCells, Inc (StemCells) is engaged in the research, development and commercialization of stem cell therapeutics. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. Its lead product development program is its central nervous system (CNS) program, in which it is developing applications for HuCNS-SC cells, its human neural platform technology.

5 Day Chart for NASDAQ:STEM

Receive News & Ratings for StemCells Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StemCells Inc. and related companies with's FREE daily email newsletter.